86. 肺動脈性肺高血圧症 Pulmonary arterial hypertension Clinical trials / Disease details
臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-001108-40-GR (EUCTR) | 04/10/2021 | 13/07/2021 | Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension | A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension - Phase 2/3 Study of MK-5475 in Adults with Pulmonary Arterial Hypertension | Pulmonary arterial hypertension MedDRA version: 20.0;Level: LLT;Classification code 10065150;Term: Associated with pulmonary arterial hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Product Name: MK-5475 Product Code: MK-5475 INN or Proposed INN: MK-5475 Other descriptive name: MK-5475 Product Name: MK-5475 Product Code: MK-5475 INN or Proposed INN: MK-5475 Other descriptive name: MK-5475 Product Name: MK-5475 Product Code: MK-5475 INN or Proposed INN: MK-5475 Other descriptive name: MK-5475 | Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 450 | Phase 2;Phase 3 | United States;Greece;Turkey;Israel;Russian Federation;Colombia;United Kingdom;Italy;France;Mexico;Canada;Argentina;Poland;Australia;Germany;New Zealand;Sweden | ||
| 2 | NCT04732221 (ClinicalTrials.gov) | May 19, 2021 | 27/1/2021 | A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007) | A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension;Hypertension, Pulmonary | Drug: MK-5475;Drug: Placebo to MK-5475 | Merck Sharp & Dohme LLC | NULL | Recruiting | 18 Years | 75 Years | All | 450 | Phase 2/Phase 3 | United States;Argentina;Australia;Belgium;Canada;Colombia;France;Germany;Greece;Israel;Italy;Mexico;New Zealand;Poland;Russian Federation;Sweden;Turkey;United Kingdom |
| 3 | EUCTR2020-001108-40-IT (EUCTR) | 21/04/2021 | 07/06/2021 | Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension | A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension - Phase 2/3 Study of MK-5475 in Adults with Pulmonary Arterial Hypertension | Pulmonary arterial hypertension MedDRA version: 20.0;Level: LLT;Classification code 10065150;Term: Associated with pulmonary arterial hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Product Name: MK-5475 Product Code: [MK-5475] INN or Proposed INN: MK-5475 Other descriptive name: MK-5475 Product Name: MK-5475 Product Code: [MK-5475] INN or Proposed INN: MK-5475 Other descriptive name: MK-5475 Product Name: MK-5475 Product Code: [MK-5475] INN or Proposed INN: MK-5475 Other descriptive name: MK-5475 | MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 450 | Phase 2;Phase 3 | United States;Portugal;Turkey;Israel;Russian Federation;Colombia;United Kingdom;Italy;France;Canada;Argentina;Poland;Australia;Germany;New Zealand;Sweden | ||
| 4 | EUCTR2020-001108-40-PL (EUCTR) | 19/04/2021 | 05/02/2021 | Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension | A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension - Phase 2/3 Study of MK-5475 in Adults with Pulmonary Arterial Hypertension | Pulmonary arterial hypertension MedDRA version: 20.0;Level: LLT;Classification code 10065150;Term: Associated with pulmonary arterial hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Product Name: MK-5475 Product Code: MK-5475 INN or Proposed INN: MK-5475 Other descriptive name: MK-5475 Product Name: MK-5475 Product Code: MK-5475 INN or Proposed INN: MK-5475 Other descriptive name: MK-5475 Product Name: MK-5475 Product Code: MK-5475 INN or Proposed INN: MK-5475 Other descriptive name: MK-5475 | Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 450 | Phase 2;Phase 3 | United States;Portugal;Turkey;Israel;Russian Federation;Colombia;United Kingdom;Italy;France;Canada;Argentina;Poland;Australia;Germany;New Zealand;Sweden | ||
| 5 | EUCTR2020-001108-40-DE (EUCTR) | 08/04/2021 | 19/01/2021 | Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension | A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension - Phase 2/3 Study of MK-5475 in Adults with Pulmonary Arterial Hypertension | Pulmonary arterial hypertension MedDRA version: 20.0;Level: LLT;Classification code 10065150;Term: Associated with pulmonary arterial hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Product Name: MK-5475 Product Code: MK-5475 INN or Proposed INN: MK-5475 Other descriptive name: MK-5475 Product Name: MK-5475 Product Code: MK-5475 INN or Proposed INN: MK-5475 Other descriptive name: MK-5475 Product Name: MK-5475 Product Code: MK-5475 INN or Proposed INN: MK-5475 Other descriptive name: MK-5475 | Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 450 | Phase 2;Phase 3 | United States;Portugal;Greece;Turkey;Israel;Russian Federation;Colombia;United Kingdom;Italy;France;Canada;Argentina;Poland;Australia;Germany;New Zealand;Sweden | ||
| 6 | NCT03744637 (ClinicalTrials.gov) | January 18, 2019 | 13/11/2018 | A Study of Single Doses of MK -5475 on Pulmonary Vascular Resistance (MK-5475-002) | A Study to Assess the Effect of Single Doses of MK -5475 on Pulmonary Vascular Resistance in Patients With Moderate to Severe Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension | Drug: MK-5475;Drug: Placebo | Merck Sharp & Dohme Corp. | NULL | Completed | 18 Years | 70 Years | All | 25 | Phase 1 | Moldova, Republic of |